Science Letter
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Science Letter
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acne
Company receives FDA nonapprovable letter for Velac
July 12th, 2005
Connetics Corp. (CNCT), a specialty-pharmaceutical company focused on dermatology, announced that the U.S. Food and Drug Administration (FDA) has issued a nonapprovable letter dated June 10, 2005, for Velac (a combination of 1% clindamycin and 0.025% tretinoin) Gel, an investigational new drug formulation for treating acne. The only issue raised in the nonapprovable letter was a positive carcinogenicity signal that was detected in a TgAC mouse dermal carcinogenicity study. "We are disappointed in the FDA's decision. As discussed during our first quarter earnings call on April 26, [2005,] we were particularly disappointed that FDA did not notify us of...
Source: Science Letter (2005-07-12)
|
